Skip to content
Sectors How it works Pricing Client stories

Insights

Companies Live signals Events Markets Trends Company lists
Log in
Platform Signal Tracker API Radar Book a 7-day Readout
Ipsen logo — Engineers and develops bacterial-based protein therapeutics...

Ipsen

Engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases

Founded 2010 France France 6518 employees Acquired Total: $277.40M Biotechnology, Pharmaceutical

General Information

Company Name Ipsen
Founded Year 2010
Location France France
Employees 6518
Industries Biotechnology, Pharmaceutical
Funding Stage Acquired
Business Model B2B, B2C
Revenue Model Product Sales, Licensing
Social

BounceWatch is an independent company data service, not affiliated with Ipsen. To contact Ipsen, visit ipsen.com.

Is this your company?

Confirm with your work e-mail, get the Verified badge and keep this profile correct yourself. Search engines and AI assistants read it every day.

Get Verified

How does Ipsen compare?

A PDF of Ipsen and up to 10 competitors you pick: team, funding, traffic and every dated move of the last 90 days. Each company is re-checked on the day you order, so it is current.

See a sample report

This takes a few seconds: we look beyond our own index too.

Meeting Ipsen soon?

A one-page PDF brief: what it does, key facts, the last 90 days of dated moves and questions worth asking. Re-checked on the day you order. See a sample

About Ipsen

Ipsen, founded in 2010, is a global biopharmaceutical company headquartered in France. The company specializes in engineering and developing bacterial-based protein therapeutics aimed at treating neurological, inflammatory, and endocrine diseases.

Focusing on three critical therapeutic areas—Oncology, Rare Disease, and Neuroscience—Ipsen has built a robust pipeline supported by its extensive nearly 100-year history in development and strategic global hubs in the U.S., France, and the U.K.. With an operational presence in over 40 countries, Ipsen ensures availability of its medicines in 88 countries through strategic international partnerships.

Noteworthy among its history of financial maneuvers is a $206.00M acquisition investment made on 01 July 2013, supported by Ipsen Ventures. This demonstrates the company's commitment to expanding its capabilities through external innovation.

Business keywords: bacterial-based protein therapeutics, neurological diseases, inflammatory diseases, endocrine diseases, oncology, rare disease, neuroscience, prostate cancer, neuroendocrine tumors, renal cell carcinoma, pancreatic cancer, peptide research, toxin research, external innovation, specialty care

Services & Products

Research and development
Pharmaceutical commercialization
Clinical trial execution
Therapeutic innovation

Target Customers

Patients with oncology needs Individuals living with rare diseases Patients with neurodegenerative conditions Healthcare providers Pharmaceutical and biotech partners

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Acquisition $206.00M 1
Ipsen Ventures
Ipsen Ventures
01 Jul 2013
Series C $29.00M 6
Seventure Partners Abingworth Ipsen Ventures
Seventure Partners, Abingworth +4
01 Nov 2010
Series B $32.00M 4
Quest for Growth SR One Johnson & Johnson Development Corporation
Quest for Growth, SR One +2
01 Oct 2007
Series A $10.40M -
01 Nov 2005

Latest News

View All
Ipsen is no longer advancing Sutro’s ADC; Layoffs at Tune Therapeutics — Endpoints.news
Ipsen is no longer advancing Sutro’s ADC; Layoffs at Tune Therapeutics
Endpoints.news Aug 08, 2025

Ipsen Alternatives & Competitors

View All Alternatives
Ipsen vs
Amgen
Amgen United States

#WeareBiotech

IPO
40947 employees
Biotechnology, Health Care
Ipsen vs
Sangamo Therapeutics, Inc.
Sangamo Therapeutics, Inc. United States

We're committed to translating our ground-breaking science into genomic medicines that transform pat...

IPO
265 employees
Biotechnology, Pharmaceutical
Ipsen vs
Odyssey Therapeutics
Odyssey Therapeutics

Building a machine learning-based platform to develop novel therapeutics focusing on cancer and auto...

IPO
127 employees
Biotechnology, Pharmaceutical
Also compare with: Ipsen vs Jazz Pharmaceuticals Jazz Pharmaceuticals View all alternatives

FAQ About Ipsen

Engineers and develops bacterial-based protein therapeutics for the treatment of neurological, inflammatory and endocrine diseases
Ipsen was founded in 2010.
Ipsen is headquartered in France.
Ipsen operates in Biotechnology and Pharmaceutical. Its work centres on bacterial-based protein therapeutics, neurological diseases, inflammatory diseases and endocrine diseases. Its customers include Patients with oncology needs, Individuals living with rare diseases and Patients with neurodegenerative conditions.
Ipsen has a B2B and B2C business model. Its revenue comes from Product Sales and Licensing.
Ipsen has approximately 6518 employees.
Ipsen has completed 4 funding rounds, raising a total of $277.40M. The latest funding stage is Acquired.
Ipsen offers: Research and development, Pharmaceutical commercialization, Clinical trial execution, Therapeutic innovation.
Top alternatives and competitors to Ipsen include Amgen, Sangamo Therapeutics, Inc., Odyssey Therapeutics, BlossomHill Therapeutics, Inc., Jazz Pharmaceuticals. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Ipsen and Amgen are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Source: BounceWatch company record for Ipsen, https://bouncewatch.com/company/ipsen, updated 11 March 2026. When citing, please name BounceWatch and link this page.

Analytics cookies (ours + Google). Cookie Policy

Talk to an analyst Book a 7-day Readout